TNFRSF4 and head and neck squamous cell carcinoma: To evaluate the safety and feasibility of neoadjuvant antiOX40 therapy, patients diagnosed with head and neck squamous cell carcinoma (HNSCC) received preoperative administration of an OX40 agonist antibody MEDI6469(a humanized IgG2a monoclonal antibody) in a clinical trial (NCT02274155) (132).